The use of different evidence-based medications and 5-year survival after an acute coronary syndrome: An observational study

International Journal of Cardiology

Volumn 132, Issue 2, 2009, Pages 197-202

  Wong, Cheuk Kit ^a   Tang, Eng Wei ^a   Herbison, Peter ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Acute coronary syndrome; Beta blockers; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; DRUG USE; EVIDENCE BASED MEDICINE; FEMALE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SURVIVAL TIME; SURVIVOR;

ACUTE CORONARY SYNDROME; EVIDENCE-BASED MEDICINE; HUMANS; SURVIVAL RATE; TIME FACTORS;

EID: 59249093989     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.11.005     Document Type: Article

References (18)

1. Mukherjee D., Fang J., Chetcuti S., Moscucci M., Kline-Rogers E., and Eagle K.A. Impact of combination evidence-based medical therapy on mortality in patients with acute coronary syndromes. Circulation 109 (2004) 745-749
2. Eagle K.A., Montoye C.K., Riba A.L., et al. Guideline-based standardized care is associated with substantially lower mortality in Medicare patients with acute myocardial infarction. J Am Coll Cardiol 46 (2005) 1242-1248
3. Smith SC, Allen J, Blair SN, Bonow RO, et al., AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. J Am Coll Cardiol 47:2130-9.
4. Eagle K.A., Lim M.J., Dabbous O.H., et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month post-discharge death in an international registry. JAMA 291 (2004) 2727-2733
5. Tang E.W., Wong C.K., and Herbison P. GRACE hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome. Am Heart J 153 (2007) 29-35 [Erratum in: Am Heart J. 2007 Nov;154(5):851]
6. Tang E.W., Wong C.K., and Herbison P. Community hospital versus tertiary hospital comparison in the treatment and outcome of patients with acute coronary syndrome: a New Zealand experience. N Z Med J 119 1238 (2006) U2078
7. Yusuf S., Peto R., Lewis J., Collins R., and Sleight P. Beta blockade during and after myocardial infarction: overview of randomized trials. Prog Cardiovascular Dis 27 (1985) 335-371
8. Ray K.K., and Cannon C.P. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndrome. J Am Coll Cardiol 46 (2005) 1425-1433
9. Danchin N., Cambou J.P., Hanania G., et al. Impact of combined secondary prevention therapy after myocardial infarction: data from a nationwide French registry. Am Heart J 150 (2005) 1147-1153
10. Wald N.J., and Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 326 (2003) 1419-1425
11. Aronow H.D., Topol E.J., Roe M.T., et al. Effect of lipid lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 357 (2001) 1063-1068
12. Briel M., Schwartz G.G., Thompson P.L., et al. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes. JAMA 295 (2006) 2046-2056
13. Ray K.K., Cannon C.P., McCabe C.H., et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndrome. J Am Coll Cardiol 46 (2005) 1405-1410
14. Hulten E., Jackson J.L., Douglas K., George S., and Vilines T.C. The effect of early, intensive statin therapy on acute coronary syndrome. A meta-analysis of randomized controlled trials. Arch Intern Med 166 (2006) 1814-1821
15. Wong C.K., and White H.D. Value of community derived risk models for stratifying patients with non-ST elevation acute coronary syndromes. Eur Heart J 26 (2005) 851-852
16. Wong C.K., and White H.D. Has the mortality rate from acute myocardial infarction fallen substantially in recent years?. Eur Heart J 23 (2002) 689-692
17. Montori V.M., Permanyer-Miralda G., Ferreira-Gonzalez I., et al. Validity of composite end points in clinical trials. BMJ 330 (2005) 594-596
18. Bogaty P., and Brophy J. Increasing burden of treatment in acute coronary syndromes: is it justified?. Lancet 361 (2003) 1813-1816